Alexion Pharmaceuticals' (ALXN) Keiser to Retire
More News related to ALXN
- Alexion to Present at the 27th Annual JP Morgan Healthcare Conference
- Alexion Pharmaceuticals (ALXN) and PDL BioPharma (PDLI) Resolve Patent Dispute
- Alexion Pharmaceuticals and PDL BioPharma Resolve Patent Dispute
- Thomas Weisel Starts Alexion Pharmaceuticals (ALXN) at Overweight
- Alexion's (ALXN) Soliris(R) Observed to Reduce Blood Measures Related to PNH
More News related to Management Changes
- Standard & Poor's Lowers Ratings on PNC Financial (PNC)
- DA Davidson Downgrades Cascade (CAE) to Underperform
- BMO Downgrades F5 Networks (FFIV) to Market Perform
- Sterne Agee Downgrades EZCorp (EZPW) to Neutral
- CL King Downgrades Steven Madden (SHOO) to Neutral
Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) announced today that David Keiser, the Company's COO since 1992 and President since 2002, will retire by the end of 2008.
Alexion Pharmaceuticals, Inc., a biotechnology company, develops and delivers life-changing drug therapies for patients with serious and life-threatening medical conditions.
Related Categories
Management ChangesStocks Mentioned
-1.02Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
